Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 891 across all filing types
Latest filing 2025-08-21 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi has completed issues of class C shares
Share Issue/Capital Change Classification · 100% confidence The document announces the completion of a directed issue of class C shares by Sobi to fulfill obligations under incentive programs. It details the subscription, payment, and subsequent repurchase plan for these shares. This falls under the category of share issuance and capital structure changes, which is specifically defined as 'Share Issue/Capital Change' (SHA).
2025-08-21 English
Sobi har genomfört emissioner av C-aktier
Share Issue/Capital Change Classification · 100% confidence The document details the completion of a share issue (C-shares) and the subsequent repurchase of those shares by the company to fulfill obligations under incentive programs. This falls under the category of share issuance and capital structure changes, specifically related to the company's own shares and capital adjustments.
2025-08-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för andra kvartalet 2025' (Interim Report for the second quarter of 2025). It contains comprehensive financial statements, including income statements, balance sheet data, and management commentary on performance for the quarter and half-year. It is a substantive financial report rather than a short announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). Q2 2025
2025-07-16 Swedish
Earnings Release 2025
Earnings Release Classification · 100% confidence The document explicitly states it is the "Q2 2025 report" and provides detailed financial figures for the Second Quarter (Q2) and the first half (H1) of 2025, including revenue, EBITA, EPS, and cash flow comparisons to the previous year. It contains a CEO statement, financial summaries in tables, and detailed breakdowns of performance metrics. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year. Therefore, it aligns best with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a comprehensive report, not just the initial highlights, and it is not a 10-K as it covers only Q2, not the full fiscal year. Q2 2025
2025-07-16 English
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under incentive programmes
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 15, 2025, announcing that the Board of Directors is exercising an authorization to repurchase shares (specifically class C shares) to secure commitments under incentive programs. This action directly relates to the company buying back or selling its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it involves an authorization from the AGM, the core action being reported is the execution of the share repurchase.
2025-07-15 English
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Transaction in Own Shares Classification · 100% confidence The document is a press release (Pressmeddelande) dated July 15, 2025, announcing that the Board of Directors has decided to utilize a repurchase authorization granted at the Annual General Meeting (AGM) to buy back C-shares issued under incentive programs. The core subject is the company's action regarding its own shares (repurchase/buyback) to fulfill obligations related to employee incentive schemes. This directly aligns with the definition for 'Transaction in Own Shares' (POS), which covers share repurchases. It is not an ER (Earnings Release) as it focuses on corporate action, not financial results. It is not a CAP (Capital/Financing Update) as it is about repurchasing existing shares, not raising new capital. It is specifically about the transaction of own shares.
2025-07-15 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.